These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12693428)

  • 1. Review of antipsychotic medication administration: a proposal of intermittent dosing.
    Boshes RA; Manschreck TC
    Schizophr Bull; 2002; 28(2):203-22. PubMed ID: 12693428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Less is more Redux: Scheduled intermittent dosing to protect/prevent cognitive deterioration in schizophrenia.
    Boshes RA; Manschreck TC
    Med Hypotheses; 2016 May; 90():79-81. PubMed ID: 27063092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimal Antipsychotic Dose and Dosing Interval in the Treatment of Schizophrenia].
    Takeuchi H
    Seishin Shinkeigaku Zasshi; 2015; 117(7):562-7. PubMed ID: 26552322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.
    Remington G; Seeman P; Feingold A; Mann S; Shammi C; Kapur S
    J Clin Psychiatry; 2011 Aug; 72(8):1042-8. PubMed ID: 20868639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment?
    Gaebel W
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 5():11-6. PubMed ID: 7622828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous versus extended antipsychotic dosing in schizophrenia: Less is more.
    Servonnet A; Uchida H; Samaha AN
    Behav Brain Res; 2021 Mar; 401():113076. PubMed ID: 33345826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®).
    Acosta FJ; Ramallo-Fariña Y; Bosch E; Mayans T; Rodríguez CJ; Caravaca A
    Schizophr Res; 2013 May; 146(1-3):196-200. PubMed ID: 23474024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent medication--an alternative?
    Gaebel W
    Acta Psychiatr Scand Suppl; 1994; 382():33-8. PubMed ID: 7916527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E; McCrone P
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine in the long-term treatment of schizophrenia.
    Kane J
    Br J Psychiatry Suppl; 1999; (37):26-9. PubMed ID: 10211138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural course of schizophrenia and effective maintenance drug treatment.
    Davis JM; Andriukaitis S
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of treatment-resistant schizophrenia.
    Conley RR; Buchanan RW
    Schizophr Bull; 1997; 23(4):663-74. PubMed ID: 9366002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.